ALKSAlkermes plc
Chart data are delayed by 15 minutes.
Main metrics
About ALKS
Alkermes plc is a global biopharmaceutical company focused on developing, manufacturing, and commercializing medicines for central nervous system disorders and other serious conditions. Its current portfolio includes treatments for schizophrenia, bipolar I disorder, alcohol dependence, opioid dependence, and narcolepsy-related symptoms, with products such as ARISTADA, ARISTADA INITIO, VIVITROL, LYBALVI, and LUMRYZ. The company works across research, clinical development, and product commercialization, using its drug formulation and delivery capabilities to support therapies designed for complex and chronic illnesses. Alkermes plc serves patients, healthcare providers, and healthcare systems in the United States, Ireland, and international markets. Founded in 1987 and headquartered in Dublin, Ireland, the company holds a notable position in the neuroscience-focused biopharmaceutical sector.
Valuation
Profitability
Balance sheet
Trading
| Issuer | Token | Chains | Dividend | Shares | Value | Share |
|---|---|---|---|---|---|---|
 Reality | rALKSAlkermes plc (Reality) |   | 0 | — | 0.0% |
| Chain | Issuers | Shares | Value | Share |
|---|---|---|---|---|
| Arbitrum One | | 0 | — | 0.0% |
| Morph | | 0 | — | 0.0% |
No dividend has been recorded for this asset.
| Date | Type | Details |
|---|---|---|
| May 15, 2000 | Stock split | 2-for-11 share → 2 shares |
Splits, mergers and other corporate actions appear here. How each issuer reflects them on-chain varies by product.
